Pulmonary embolism can be fatal, but most people who receive timely treatment survive. The overall picture depends heavily on severity: patients with massive PE (where blood pressure drops dangerously low) face a 90-day mortality rate of about 52%, while those with non-massive PE have a 90-day mortality rate closer to 15%. That gap makes early recognition and rapid treatment the single biggest factor in survival.
Why Pulmonary Embolism Can Kill
A pulmonary embolism is a blood clot that lodges in the arteries of the lungs. When a clot blocks enough of the pulmonary blood vessels, it sharply increases the resistance the right side of the heart has to pump against. If that resistance climbs too high, the right ventricle simply can’t keep up. Blood stops flowing forward effectively, oxygen levels plummet, and the body goes into a form of shock called obstructive shock.
In the most severe cases, this chain of events happens within minutes. Some people collapse or lose consciousness before they even realize something is wrong. That’s why PE is sometimes described as a cause of “sudden death,” though most cases give warning signs before reaching that point.
Warning Signs That Need Immediate Attention
The hallmark symptoms of pulmonary embolism are sudden shortness of breath, sharp chest pain that worsens when you breathe in, and fainting. Shortness of breath appears even at rest and gets worse with any physical activity. The chest pain is often mistaken for a heart attack because it can feel intense and crushing, though it typically sharpens with deep breaths, coughing, or bending over.
Other signs include a rapid or irregular heartbeat, dizziness, and skin that looks pale, bluish, or clammy. Fainting is especially concerning because it signals that your heart rate or blood pressure has dropped suddenly. Any combination of unexplained breathlessness, chest pain, or loss of consciousness warrants emergency care.
How Severity Determines the Odds
Not all pulmonary embolisms carry the same risk. Doctors classify PE by how much it affects your cardiovascular system, and the difference in outcomes between categories is dramatic.
Data from the International Cooperative Pulmonary Embolism Registry found that about 4.5% of PE cases are “massive,” meaning blood pressure drops below a critical threshold. Those patients had a 90-day mortality rate of 52.4%. The remaining 95.5% of cases, where blood pressure stayed stable, had a 90-day mortality rate of 14.7%. That 14.7% still isn’t trivial, which is why even a “non-massive” PE requires treatment and monitoring.
Clinicians use scoring systems to further sort patients by risk. When patients are grouped into low-risk and high-risk categories using these tools, the mortality rate for low-risk patients drops to about 0.6%, while high-risk patients face a mortality rate around 10.4%. In studies tracking outcomes across five risk classes, the two lowest classes had zero deaths, while the highest class had a mortality rate of 13%.
What Treatment Looks Like
For most patients, treatment centers on blood thinners (anticoagulants), which prevent existing clots from growing and new clots from forming while the body gradually breaks down the blockage. Many people with low-risk PE can even be treated at home after an initial evaluation, though higher-risk patients need hospitalization.
When PE causes dangerously low blood pressure or the heart is failing, more aggressive options come into play. These include clot-dissolving medications delivered through an IV or a catheter threaded directly to the clot, mechanical devices that physically break up or remove the clot, and in rare cases, open surgery. Patients in this category may also need support for breathing and circulation while their bodies stabilize. The 2026 AHA/ACC guidelines recommend hospitalization for anyone showing signs of heart strain, rising biomarkers, or cardiovascular instability.
Recurrence Risk After the First Event
Surviving one pulmonary embolism doesn’t eliminate future risk. For people whose first clot had no clear trigger (no surgery, no immobilization, no hormonal medication), the chance of recurrence is significant. A large meta-analysis published in The BMJ found that after stopping anticoagulant treatment, about 10 out of every 100 patients experienced another clot within the first year. The cumulative recurrence rate climbed to 16% at two years, 25% at five years, and 36% at ten years.
The recurrence rate drops over time on a per-year basis, falling from about 10% in the first year to roughly 3% per year by years six through ten. But the risk never fully disappears, which is why some patients stay on blood thinners indefinitely. Each recurrent clot event carries about a 4% chance of being fatal. That ongoing risk is a major reason doctors weigh the benefits of long-term anticoagulation against its bleeding risks for each individual patient.
Long-Term Complications to Watch For
Even after successful treatment, some people develop a chronic condition where old clot material scars into the walls of the pulmonary arteries and permanently raises the blood pressure in the lungs. This condition, called chronic thromboembolic pulmonary hypertension (CTEPH), develops in roughly 2.3% of PE patients within three years. It shows up gradually: most cases are detected between six months and two years after the initial event.
CTEPH causes persistent shortness of breath with exertion, fatigue, and reduced exercise tolerance. It’s treatable, often with surgery to remove the scarred clot material or with medications that lower pulmonary blood pressure. The key is recognizing that breathlessness lingering months after a PE isn’t necessarily just slow recovery. It may signal a complication that needs its own diagnosis and treatment plan.